Vontobel Holding Ltd. Sells 39,231 Shares of Edwards Lifesciences Co. (NYSE:EW)

Vontobel Holding Ltd. cut its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 8.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 399,875 shares of the medical research company's stock after selling 39,231 shares during the period. Vontobel Holding Ltd. owned 0.07% of Edwards Lifesciences worth $29,603,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the fourth quarter worth $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the third quarter worth $32,000. Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Finally, JFS Wealth Advisors LLC raised its holdings in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock worth $46,000 after purchasing an additional 166 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock worth $2,002,829 in the last quarter. 1.29% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EW has been the subject of several research reports. Daiwa America lowered shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 30th. Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Robert W. Baird cut their price target on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. Finally, Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Stock Up 0.0 %

NYSE:EW traded up $0.00 during trading hours on Tuesday, hitting $76.19. 1,944,755 shares of the company's stock traded hands, compared to its average volume of 4,474,389. The stock's fifty day moving average price is $72.78 and its two-hundred day moving average price is $69.68. The firm has a market cap of $44.94 billion, a P/E ratio of 10.99, a P/E/G ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.